Atara Biotherapeutics
ATRA
154 hedge funds and large institutions have $376M invested in Atara Biotherapeutics in 2022 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 63 increasing their positions, 28 reducing their positions, and 20 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 28
100% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 20
15% more funds holding
Funds holding: 134 → 154 (+20)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.06% less ownership
Funds ownership: 4.27% → 4.22% (-0.06%)
52% less capital invested
Capital invested by funds: $776M → $376M (-$400M)
67% less call options, than puts
Call options by funds: $114K | Put options by funds: $342K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$13.5M |
| 2 |
D.E. Shaw & Co
New York
|
+$9.22M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.43M |
| 4 |
Goldman Sachs
New York
|
+$8.18M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$4.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$25.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17.3M |
| 3 |
EC
Eminence Capital
New York
|
-$10.3M |
| 4 |
AG
Artal Group
Luxembourg
|
-$7.79M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$4.81M |
ATRA Hedge Fund Activity: Q3 2022 in Review
154 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q3 2022, worth a combined $376M — down 52% from $776M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new ATRA positions and 20 closed out — a net gain of 20 holders — while 63 added to existing stakes and 28 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $13.5M. The largest seller was Fidelity Investments, cutting an estimated $25.3M.
- 154 institutional investors held Atara Biotherapeutics (ATRA) as of Q3 2022, up from 134 in Q2 2022.
- Funds reported $376M of Atara Biotherapeutics stock for Q3 2022, down 52% quarter-over-quarter.
- 40 funds opened new Atara Biotherapeutics positions in Q3 2022 and 20 closed out, a net change of +20 holders.
- The largest Atara Biotherapeutics buyer in Q3 2022 was Wasatch Advisors, an estimated $13.5M added.
- The largest Atara Biotherapeutics seller in Q3 2022 was Fidelity Investments, an estimated $25.3M sold.
Based on aggregated 13F filings for Q3 2022.